

Notes on Exact Power Calculations for t Tests and Analysis of Covariance

Yongqiang Tang *

Tesaro, 1000 Winter St, Waltham, MA 02451

March 13, 2024

Abstract

[Tang \(2018b,a\)](#) derived the exact power formulae for t tests and analysis of covariance (ANCOVA) in superiority, noninferiority and equivalence trials. The power calculation in equivalence trials can be simplified by using Owen's Q function, which is available in standard statistical software. We extend the exact power determination method for ANCOVA to unstratified and stratified multi-arm randomized trials. The method is applied to the design of multi-arm trials and gold standard noninferiority trials

Keywords: Gold standard noninferiority trial, linear contrast, multi-arm randomized trial, pre-stratification factor

1 Introduction

[Tang \(2018a,b\)](#) obtained the exact power formulae for some commonly used t tests in superiority, noninferiority (NI) and equivalence trials. The power determination for the analysis of covariance (ANCOVA) and t-test with unequal variances in equivalence trials involves two-dimensional numerical integration. We show that the calculation can be simplified by using Owen's Q function, which is available in standard statistical software packages (e.g. SAS and R *PowerTOST*). We extend the method for ANCOVA to unstratified and stratified multi-arm randomized trials, and apply it to the power determination for multi-arm trials and gold standard NI trials ([Pigeot et al., 2003](#)).

*email: yongqiang_tang@yahoo.com

We use the same notations as [Tang \(2018a,b\)](#). Let $t(f, \lambda)$ denote the t distribution with f degrees of freedom and noncentrality parameter λ , $t_{f,p}$ the p th percentile of the central t distribution, $\Phi(\cdot)$ the cumulative distribution function (CDF) of $N(0, 1)$, $F_{f_1, f_2}(\cdot)$ the CDF of a central $F(f_1, f_2)$ distribution, and $Q_f(t, \delta; a, b) = \frac{1}{\Gamma(f/2)2^{f/2-1}} \int_a^b \Phi(\frac{tx}{\sqrt{f}} - \delta) x^{f-1} \exp(-\frac{x^2}{2}) dx$ Owen's Q function. Let n_g be the number of subjects in group g , n the total size, M_0 the superiority ($M_0 = 0$) or NI margin, and (M_l, M_u) the lower and upper equivalence margins. Without loss of generality, we assume high scores indicate better health.

2 Two sample t tests

Let $(\hat{\tau}, n^{-1}\hat{V})$ be the estimated effect and variance with true values $(\tau_1, n^{-1}V)$ in a test based on the t distribution. Suppose $\frac{\hat{\tau}-\tau_1}{\sqrt{n^{-1}\hat{V}}} \sim N(0, 1)$ is independent of $\xi = \frac{\hat{V}}{V} \sim \frac{\chi_f^2}{f}$. In superiority and NI trials, we reject the null hypothesis when $t = \frac{\hat{\tau}-M_0}{\sqrt{n^{-1}\hat{V}}} > C = t_{f, 1-\alpha/2}$. If f and V are known, the exact power is $\Pr \left[t(f, \frac{|\tau_1-M_0|}{\sqrt{n^{-1}V}}) > C \right]$, or 1 minus the CDF of $t \sim t(f, \frac{|\tau_1-M_0|}{\sqrt{n^{-1}V}})$ evaluated at C .

An equivalence test is significant if both $t_l = \frac{\hat{\tau}-M_l}{\sqrt{n^{-1}\hat{V}}} > C$ and $t_u = \frac{\hat{\tau}-M_u}{\sqrt{n^{-1}\hat{V}}} < -C$. By the change of variable $x = \sqrt{f\xi}$, the exact power equation (26) of [Tang \(2018b\)](#) can be rearranged in terms of Owen's Q function as

$$P_{\text{equi}} = \int_0^{\frac{(M_u-M_l)^2}{4n^{-1}VC^2}} \left[\Phi(\delta_1 - C\sqrt{\xi}) - \Phi(\delta_2 + C\sqrt{\xi}) \right] dG(\xi) = Q_f(-C, \delta_2; 0, R) - Q_f(C, \delta_1; 0, R) \quad (1)$$

where $G(\xi)$ is the CDF of $\xi \sim \frac{\chi_f^2}{f}$, $\delta_2 = \frac{M_l-\tau_1}{\sqrt{n^{-1}V}} < 0$, $\delta_1 = \frac{M_u-\tau_1}{\sqrt{n^{-1}V}} > 0$ and $R = \frac{\sqrt{f}(\delta_1-\delta_2)}{2C}$.

In the t test with unequal variances [i.e. $y_{0i} \stackrel{iid}{\sim} N(\mu_0, \sigma_0^2)$, $y_{1i} \stackrel{iid}{\sim} N(\mu_1, \sigma_1^2)$], the power of the superiority and NI trial is obtained from the fact ([Moser et al., 1989](#); [Tang, 2018b](#)) that $\frac{\hat{\tau}-M_0}{\sqrt{n^{-1}\hat{V}}} h^*(u) = \frac{\hat{\tau}-M_0}{\sqrt{n^{-1}V}} \sqrt{\frac{n-2}{(n_1-1)s_1^2/\sigma_1^2 + (n_0-1)s_0^2/\sigma_0^2}}$ follows a noncentral $t(n-2, \frac{|\tau_1-M_0|}{\sqrt{n^{-1}V}})$ distribution given u

$$P_{\text{sup/ni}} = \int_0^\infty \Pr \left[t \left(n-2, \frac{|\tau_1-M_0|}{\sqrt{n^{-1}V}} \right) > h(u) \right] dF_{n_1-1, n_0-1}(u) \quad (2)$$

where $\hat{\tau} = \hat{\mu}_1 - \hat{\mu}_0$, s_g^2 is the sample variance in group g , $n^{-1}\hat{V} = \frac{s_1^2}{n_1} + \frac{s_0^2}{n_0}$, $n^{-1}V =$

$\frac{\sigma_1^2}{n_1} + \frac{\sigma_0^2}{n_0}$, $u = \frac{s_1^2/\sigma_1^2}{s_0^2/\sigma_0^2} \sim F(n_1 - 1, n_0 - 1)$, and

$$\begin{aligned} h^*(u) &= \sqrt{\frac{(n-2)[u\sigma_1^2/n_1 + \sigma_0^2/n_0]}{n^{-1}V[(n_1-1)u + n_0 - 1]}}, \\ f(u) &= \frac{[u\sigma_1^2/n_1 + \sigma_0^2/n_0]^2}{u^2\sigma_1^4/[n_1^2(n_1-1)] + \sigma_0^4/[n_0^2(n_0-1)]}, \\ h(u) &= t_{f(u), 1-\frac{\alpha}{2}} h^*(u). \end{aligned}$$

The exact equivalence power (equation (A3) of [Tang \(2018b\)](#)) can be reexpressed as

$$P_{\text{equi}} = \int_0^\infty \{Q_{n-2}[-h(u), \delta_2; 0, R(u)] - Q_{n-2}[h(u), \delta_1; 0, R(u)]\} dF_{n_1-1, n_0-1}(u) \quad (3)$$

where $\delta_2 = \frac{M_l - \tau_l}{\sqrt{n^{-1}V}}$, $\delta_1 = \frac{M_u - \tau_l}{\sqrt{n^{-1}V}}$ and $R(u) = \frac{\sqrt{n-2}(\delta_1 - \delta_2)}{2h(u)}$. Please see [Tang \(2018b\)](#) for numerical examples.

3 ANCOVA

[Tang \(2018a,b\)](#) derived the exact power formulae for ANCOVA analysis of two-arm trials. Below we present more general results for unstratified or stratified multi-arm randomized trials. Suppose subjects are randomized to $K^* = K + 1$ treatment groups ($g = 0, \dots, K$) within each of h strata. In an unstratified trial, we set $h = 1$. Subjects in treatment group g are modeled by

$$y_{gi} = \mu_g + z_{gi_1}\alpha_1 + \dots + z_{gi_{r-1}}\alpha_{r-1} + \mathbf{x}'_{gi}\boldsymbol{\beta} + \varepsilon_{gi} = \eta + \delta_g + z_{gi_1}\alpha_1 + \dots + z_{gi_{r-1}}\alpha_{r-1} + \mathbf{x}'_{gi}\boldsymbol{\beta} + \varepsilon_{gi}$$

where z_{gi_k} ($k = 1, \dots, r-1$) is the indicator variable for the pre-stratification factors, μ_g is the effect for treatment group g , $\mathbf{x}_{gi}$ is the $q \times 1$ vector of baseline covariates, $\varepsilon_{gi} \sim N(0, \sigma^2)$, $\eta = \mu_0$ and $\delta_g = \mu_g - \mu_0$. In general, r equals the number of strata h . In trials with multiple stratification factors, $r < h$ if there is no interaction between some stratification factors. By the same arguments as the proof of equation (15) in [Tang \(2018a\)](#), we obtain the variance for the linear contrast with coefficients $(l_0, \dots, l_K)'$

$$\text{var} \left(\sum_{g=0}^K l_g \hat{\mu}_g \right) = \sigma^2 V_l \left(1 + \frac{q}{n - q - r - K + 1} \tilde{\Upsilon} \right)$$

where $\sum_{g=0}^K l_g = 0$, $\bar{\mathbf{z}}_g$ is the mean of $\mathbf{z}_{gi} = (z_{gi_1}, \dots, z_{gi_{r-1}})'$ in group g , $S_{zz} = \sum_{g=0}^K \sum_{i=1}^{n_g} (\mathbf{z}_{gi} - \bar{\mathbf{z}}_g)^{\otimes 2}$, $\tilde{\Upsilon}$ is a function of the covariate $\mathbf{x}_{gi}$'s, and $V_l = \sum_g l_g^2/n_g + (\sum_g l_g \bar{\mathbf{z}}_g)' S_{zz}^{-1} (\sum_g l_g \bar{\mathbf{z}}_g)$. In a two arm trial ([Tang, 2018a](#)), $V_l = \left[\sum_{s=1}^h \frac{n_{s1}n_{s0}}{n_{s1}+n_{s0}} \right]^{-1}$

if there is no restriction on the stratum effect (i.e. $r = h$), where n_{sg} is the number of subjects in stratum s , treatment group g . A constant treatment allocation ratio is commonly used in practice. Then $\bar{z}_0 = \dots = \bar{z}_K$ and $V_l = \sum_g l_g^2/n_g$. Let $\tau_1 = \sum_g l_g \mu_g$, $f = n - q - r - K$, and $f_2 = f + 1$. When $\mathbf{x}_{gi}$'s are normally distributed, $\tilde{Y} \sim F(q, f_2)$ and the exact power for the superior or NI test is

$$P_{\text{sup/ni}} = \int_0^\infty \Pr \left[t \left(f, \sqrt{\frac{(\tau_1 - M_0)^2}{\sigma^2 V_l (1 + q \tilde{Y}/f_2)}} \right) > t_{f, 1-\frac{\alpha}{2}} \right] dF_{q, f_2}(\tilde{Y}). \quad (4)$$

Formula (4) also provides very accurate power estimate for nonnormal covariates (Tang, 2018b). In equivalence trials, the exact power is

$$P_{\text{equi}} = \int_0^\infty \left\{ Q_f \left[-t_{f, 1-\alpha/2}, \delta_2(\tilde{Y}); 0, R(\tilde{Y}) \right] - Q_f \left[t_{f, 1-\alpha/2}, \delta_1(\tilde{Y}); 0, R(\tilde{Y}) \right] \right\} dF_{q, f_2}(\tilde{Y}) \quad (5)$$

where $\delta_2(\tilde{Y}) = \frac{M_l - \tau_1}{\sqrt{\sigma^2 V_l (1 + q \tilde{Y}/f_2)}} < 0$, $\delta_1(\tilde{Y}) = \frac{M_u - \tau_1}{\sqrt{\sigma^2 V_l (1 + q \tilde{Y}/f_2)}} > 0$ and $R(\tilde{Y}) = \frac{\sqrt{f}(\delta_1 - \delta_2)}{2t_{f, 1-\alpha/2}}$. The exact power formulae (equation (A1) of Tang (2018b), equation (30) of Tang (2018a)) for two arm trials are equivalent to equation (5) at $K = 1$.

The power formulae (2), (3), (4) and (5) are of the form $\int_0^\infty P_c(x) dF_{f_1, f_2}(x)$, and can be calculated as

$$P = \int_0^\infty P_c(x) dF_{f_1, f_2}(x) = \int_0^1 P_c \left[F_{f_1, f_2}^{-1}(\nu) \right] d\nu. \quad (6)$$

Below we give three hypothetical examples. Sample R code is provided in the Supplementary Material. In each example, the simulated (SIM) power is evaluated based on 4,000,000 simulated datasets. There is more than 95% chance that the SIM power lies within 0.05% of the true power. In example 1, we perform the power calculation for a superiority trial. Subjects are randomized equally into $K^* = 3$ groups ($K = 2$ experimental, or control treatment) stratified by gender ($z_{gi_1} = 1$ for male, 0 for female) and age ($z_{gi_2} = 1$ if old, 0 otherwise). There are 6 subjects per treatment group per stratum ($n_0 = n_1 = n_2 = 24$, $n = 72$). There is no interaction between age and gender ($r = 3$, $h = 4$), and the outcome is normally distributed as

$$y_{gi} \sim N[\mu_g + 0.6 z_{gi_1} + 0.3 z_{gi_2} + 0.5 x_{gi}, 1]$$

where $(\mu_0, \mu_1, \mu_2) = (0, 0.6, 0.9)$ and $x_{gi} \sim N(0.2 z_{gi_1} + 0.4 z_{gi_2}, 1)$. We compare each experimental treatment versus control treatment at the Bonferroni-adjusted one tailed significance level of $\alpha/2 = 0.0125$. The exact power by formula (4) is 78.63% and 41.39%, and the SIM power is 78.62% and 41.39% respectively for the two tests.

Example 2 has similar setup to example 1 except that $(\mu_0, \mu_1, \mu_2) = (0, 0.05, 0.1)$

and the sample size is 30 per group per stratum ($n_0 = n_1 = n_2 = 120$, $n = 360$). The aim is to establish the equivalence of each experimental treatment versus control treatment at $\alpha/2 = 0.0125$. The margin is $(M_l, M_u) = (-0.5, 0.5)$. The exact power by formula (5) is 79.14% and 86.72% respectively for the two tests, while the SIM power is 79.14% and 86.71%.

In example 3, we design a three-arm “gold standard” NI trial (Pigeot et al., 2003). It consists of placebo ($g = 0$), an active control treatment ($g = 1$) and an experimental treatment ($g = 2$). The set up is similar to example 1 except that $(\mu_0, \mu_1, \mu_2) = (0, 1, 1.1)$, and the sample size is 10 per group per stratum ($n_0 = n_1 = n_2 = 40$, $n = 120$). Two tests are conducted at the one-sided significance level of $\alpha/2 = 0.025$. Test 1 evaluates the superiority of treatment 1 over placebo. The power for this test (exact $P_1 = 99.29\%$, SIM 99.28%) is very close to 1. In test 2, we assess the noninferiority of treatment 2 to treatment 1 by demonstrating that treatment 2 preserves at least 50% of the efficacy of treatment 1 compared to placebo (i.e. $\frac{\mu_2 - \mu_0}{\mu_1 - \mu_0} > 50\%$ or $\mu_2 - 0.5\mu_1 - 0.5\mu_0 > 0$). The exact power of test 2 is $P_2 = 86.41\%$ (SIM power 86.41%). The noninferiority is claimed only if both tests are significant (Pigeot et al., 2003), and the overall power is at least $P_1 + P_2 - 1 = 85.70\%$ while the simulated power is 85.80%.

References

- Moser, B. K., G. R. Stevens, and C. L. Watts (1989). The two-sample t test versus Satterthwaite’s approximate F test. *Communications in Statistics – Theory and Methods* 18, 3963 – 75.
- Pigeot, I., J. Schafer, J. Rohmel, and D. Hauschke (2003). Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo. *Statistics in Medicine* 22, 883 – 99.
- Tang, Y. (2018a). Exact and approximate power and sample size calculations for analysis of covariance in randomized clinical trials with or without stratification. *Statistics in Biopharmaceutical Research* 10, 274 – 286.
- Tang, Y. (2018b). A noniterative sample size procedure for tests based on t distributions. *Statistics in Medicine* 37, 3197 – 213.